Table 6.

Multivariate analyses (cox regression) of overall survival^a in younger and older patients

Variables	Patients ≦ 60 y/o				Patients > 60 y/o
		95% CI				95% CI
	HR	Lower	Upper	P	HR	Lower	Upper	P
NPM1b	0.000	0.000	1.490E89	0.898	0.263	0.021	3.377	0.305
FLT3-ITDc	7.505	1.538	36.614	0.013*	3.235	0.424	24.699	0.258
FLT3-TKD	9765.104	32.249	2.95E6	0.002*	144.617	0.000	3.75E169	0.980
CEBPAd	0.357	0.125	1.020	0.054	1.090	0.292	4.066	0.898
IDH1b	14220.871	0.000	3.9E99	0.932	174.990	0.000	4.56E169	0.979
IDH2b	0.000	0.000	2.695E210	0.958	0.459	0.050	4.242	0.492
DNMT3Ab	146.313	0.000	4.16E97	0.965
MLLb	0.059	0.000	1.78E94	0.980	2.245	0.173	29.122	0.536
MN1e	1.923	1.130	3.273	0.016*	1.198	0.916	1.567	0.187
ERG	53.777	1.820	1589.377	0.021*	32.349	2.889	362.237	0.005*
miR-181a	0.514	0.260	1.014	0.055	1.361	0.933	1.986	0.110
miR-3151	1.164	0.580	2.337	0.669	0.423	0.191	0.935	0.033*
BDH2e	4.829	1.002	23.274	0.050*	18.937	1.571	228.308	0.021*

Abbreviations: HR indicates Hazard ratio; CI, confidence interval.

^aOnly patients with intensive induction chemotherapy enrolled.

^bNPM1^mut versus NPM1^{wild type}; IDH1^mut versus IDH1^{wild type}; IDH2^mut versus IDH2^{wild type}; DNMT3A^mut versus DNMT3A^wild type.

^cFLT3-ITD^mut versus FLT3-ITD^neg.

^dCEBPA^{double-mutation} versus CEBPA^{single mutation} versus CEBPA^{no mutation}.

^eBDH2^high relative to BDH2^low group.

*Statistically significant (P < 0.05).